94 results
8-K
CLNN
Clene Inc
9 Apr 24
Entry into a Material Definitive Agreement
5:20pm
specialty health clinic. The NIH Grant will support an Expanded Access Program (the “NIH EAP”) for CNM-Au8 treatment of amyotrophic lateral sclerosis (“ALS … ”), and was awarded under the Accelerating Access to Critical Therapies for ALS Act. On April 3, 2024, the Company entered into a grant subaward
8-K
EX-10.1
CLNN
Clene Inc
9 Apr 24
Entry into a Material Definitive Agreement
5:20pm
Greenberg
PTE Federal Award No: 1U01NS136023-01
Subaward No: 2(GG011355-01)
Project Title: Intermediate-sized Expanded Access Protocol for CNM-Au8 … (defined as listed on the NOA).
Treatment of program income: Additive
Special Terms and Conditions:
Data Sharing and Access:
Subrecipient agrees to comply
8-K
EX-99.1
CLNN
Clene Inc
13 Mar 24
Clene Reports Full Year 2023 Financial Results
8:02am
) in Expanded Access Program (EAP) participants (n=220) treated with CNM-Au8 compared to historical ALS disease progression controls with decreased risk … shown to be dysregulated in neurodegenerative diseases. The article is available via Open Access at: https://jnanobiotechnology.biomedcentral.com
8-K
41z7mu 58r3ir9kcfu
22 Feb 24
Regulation FD Disclosure
8:04am
8-K
EX-99.2
wwjrkdc5uw xo
22 Feb 24
Regulation FD Disclosure
8:04am
8-K
EX-99.3
dntk32xal8y
21 Dec 23
Regulation FD Disclosure
7:00am
424B5
7czp7glcizx drzpjsu
7 Nov 23
Prospectus supplement for primary offering
8:05am
8-K
EX-99.1
gi3m6v
7 Nov 23
Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
8:02am
424B3
1gac42bbfkfw98
6 Oct 23
Prospectus supplement
4:11pm
8-K
EX-99.2
fh6l7v1
25 Sep 23
Regulation FD Disclosure
7:01am
8-K
EX-99.2
m95p7qfo7saae85yp4ao
29 Aug 23
Regulation FD Disclosure
7:05am
8-K
EX-4.1
t2g1ickvj7t81r97at5
30 Jun 23
Entry into a Material Definitive Agreement
4:04pm
8-K
EX-1.1
42wdjo9xiug4q 65a
16 Jun 23
Clene Announces Launch of Proposed Public Offering
5:06pm